The short answer
An added stimulant effect from caffeine with pentoxifylline is not established. Review caffeine intake and any history of caffeine intolerance with your prescriber.
What this answer covers
Oral caffeine from supplements or drinks; dose and timing vary. Exact oral extended-release pentoxifylline treatment.
- Supplement or preparation
- Caffeine
- Medication ingredient
- pentoxifylline
Separate caffeine effects from an interaction
An original study found that 400 mg caffeine disrupted sleep even when taken six hours before bedtime. It did not involve pentoxifylline. This demonstrates a caffeine effect at a tested dose, not that pentoxifylline amplifies it.
The label’s caffeine warning concerns intolerance
Pentoxifylline labeling says it should not be used in people who previously showed intolerance to caffeine or other methylxanthines. Tell the prescriber about the nature of any previous reaction. This is a different issue from assuming that all people who drink coffee will develop a drug interaction.
Theophylline is a separate medicine
The label reports that pentoxifylline can raise theophylline levels. It also warns about strong CYP1A2 inhibitors increasing pentoxifylline exposure. Neither statement establishes the same effect for caffeine. Shared chemical family or metabolism alone is insufficient.
Review total intake and new symptoms
Tell your pharmacist about caffeine tablets, energy products and drinks so total intake can be assessed. Report new persistent palpitations, dizziness, anxiety or sleep disruption. There is no established caffeine-specific pentoxifylline dose change or protective hours-apart rule; follow the prescribed extended-release regimen with meals.
Evidence and practical considerations
Side effects & toxicity
An increase in stimulant effects specifically caused by combining caffeine with pentoxifylline has not been established.
- Exact scope
- Oral caffeine from supplements or drinks; dose and timing vary. Exact oral extended-release pentoxifylline treatment. with Exact pentoxifylline RxCUI 8013 IN confirmed by current RxNorm. Oral extended-release 400 mg tablets for intermittent claudication; experimental immediate-release, intravenous and other-drug exposures are distinct.
- Medication form and route
- Oral
What remains uncertain
- Pentoxifylline’s theophylline interaction and strong CYP1A2-inhibitor warning do not establish a caffeine interaction. Prior methylxanthine intolerance is a separate contraindication. Caffeine sleep effects do not prove additive toxicity.
Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.
Read the supporting source summaries
Source 1: Current prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with intermittent claudication due to chronic occlusive arterial disease.
Bleeding reported with or without NSAIDs, anticoagulants or platelet inhibitors. Prior methylxanthine intolerance, including caffeine, is a contraindication. Pentoxifylline can raise theophylline levels; strong CYP1A2 inhibitors can raise pentoxifylline exposure.
How this applies: Exact drug/formulation guidance. Exact pentoxifylline RxCUI 8013 IN confirmed by current RxNorm. Oral extended-release 400 mg tablets for intermittent claudication; experimental immediate-release, intravenous and other-drug exposures are distinct.
Does not establish an interaction with every supplement, or transfer theophylline effects to caffeine. Occasional hypotension/arrhythmia reports were not more frequent than placebo in controlled trials. Immediate-release adverse-event results differ from extended-release.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Participants assessed for sleep effects in the home setting.
Sleep was disrupted at each tested timing.
How this applies: Interpret exact preparation, comparator and endpoint; no automatic combination causality.
Abstract-only; fullTextXML attempt failed. No pentoxifylline, no evidence of amplified stimulation from co-use and no universal safe-dose cutoff.
Source 3: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
Pentoxifylline, IN.
How this applies: Exact identity.
Not clinical evidence.
Research assessment: · Open full citations ↗
Side effects & toxicity
A history of intolerance to caffeine or related methylxanthines needs prescriber review before pentoxifylline use.
- Exact scope
- Oral caffeine from supplements or drinks; dose and timing vary. Exact oral extended-release pentoxifylline treatment. with Exact pentoxifylline RxCUI 8013 IN confirmed by current RxNorm. Oral extended-release 400 mg tablets for intermittent claudication; experimental immediate-release, intravenous and other-drug exposures are distinct.
- Medication form and route
- Oral
What remains uncertain
- Exact label contraindication for previous intolerance, not a universal caffeine prohibition or measured combination stimulation.
Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.
Read the supporting source summaries
Source 1: Current prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with intermittent claudication due to chronic occlusive arterial disease.
Bleeding reported with or without NSAIDs, anticoagulants or platelet inhibitors. Prior methylxanthine intolerance, including caffeine, is a contraindication. Pentoxifylline can raise theophylline levels; strong CYP1A2 inhibitors can raise pentoxifylline exposure.
How this applies: Exact drug/formulation guidance. Exact pentoxifylline RxCUI 8013 IN confirmed by current RxNorm. Oral extended-release 400 mg tablets for intermittent claudication; experimental immediate-release, intravenous and other-drug exposures are distinct.
Does not establish an interaction with every supplement, or transfer theophylline effects to caffeine. Occasional hypotension/arrhythmia reports were not more frequent than placebo in controlled trials. Immediate-release adverse-event results differ from extended-release.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: 9d3cd9836ca1c244
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.